Institute For Molecular Medicine

This early-stage study tests a vaccine called AV-1959D in 48 people with early Alzheimer's disease. The vaccine aims to train the immune system to target harmful amyloid plaques in the brain. The main goal is to check if the vaccine is safe and tolerable.